SEC 13F Intelligence

Farallon Capital Management, L.L.C. / PTGX

Farallon Capital Management, L.L.C.’s Protagonist Therapeutics Inc Position

Does Farallon Capital Management, L.L.C. own Protagonist Therapeutics Inc (PTGX)? Yes — 6.35M shares worth $669M (+3.63% of its 13F portfolio) as of Q1 2026, up from 6.14M shares the prior filed quarter.

Position Value
$669M
Q1 2026
Shares
6.35M
% of Portfolio
+3.63%
Quarters Held
30
currently held

Position History PTGX

Reported value by quarter
Q4 ’18: $15MQ4 ’18Q1 ’19: $23MQ2 ’19: $18MQ3 ’19: $18MQ4 ’19: $11MQ4 ’19Q1 ’20: $11MQ2 ’20: $44MQ3 ’20: $54MQ4 ’20: $49MQ4 ’20Q1 ’21: $63MQ2 ’21: $105MQ3 ’21: $42MQ4 ’21: $66MQ4 ’21Q1 ’22: $27MQ2 ’22: $29MQ3 ’22: $31MQ4 ’22: $40MQ4 ’22Q1 ’23: $60MQ2 ’23: $125MQ3 ’23: $91MQ4 ’23: $131MQ4 ’23Q1 ’24: $166MQ2 ’24: $202MQ3 ’24: $264MQ4 ’24: $229MQ4 ’24Q1 ’25: $295MQ2 ’25: $341MQ3 ’25: $412MQ4 ’25: $537MQ4 ’25Q1 ’26: $669Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20266.35M$669M+3.63%
Q4 20256.14M$537M+2.53%
Q3 20256.20M$412M+1.68%
Q2 20256.17M$341M+1.44%
Q1 20256.11M$295M+1.58%
Q4 20245.93M$229M+1.16%
Q3 20245.86M$264M+1.28%
Q2 20245.84M$202M+0.95%
Q1 20245.74M$166M+0.75%
Q4 20235.73M$131M+0.58%
Q3 20235.45M$91M+0.39%
Q2 20234.51M$125M+0.70%
Q1 20232.62M$60M+0.30%
Q4 20223.65M$40M+0.26%
Q3 20223.65M$31M+0.17%
Q2 20223.70M$29M+0.17%
Q1 20221.13M$27M+0.12%
Q4 20211.92M$66M+0.34%
Q3 20212.39M$42M+0.20%
Q2 20212.33M$105M+0.43%
Q1 20212.42M$63M+0.35%
Q4 20202.42M$49M+0.31%
Q3 20202.75M$54M+0.38%
Q2 20202.50M$44M+0.36%
Q1 20201.50M$11M+0.07%
Q4 20191.50M$11M+0.08%
Q3 20191.50M$18M+0.15%
Q2 20191.50M$18M+0.15%
Q1 20191.79M$23M+0.18%
Q4 20182.20M$15M+0.12%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Farallon Capital Management, L.L.C.’s full portfolio or all institutional holders of PTGX.